Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill more
tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the
amount of normal tissue that needs to be removed.
PURPOSE: This phase I trial is studying the side effects and best dose of liposomal
doxorubicin when given before mastectomy in treating women with invasive breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins